Thank you to our sponsors!
2
ASH 2021 OVERVIEW Virtual/ Live (hybrid) 879 “myeloma related” abstracts Many important reports on biology, diagnostics and trials follow-up 3
iStopMM abstracts for ASH 6 ASH Abstracts for 2021 4 oral presentations Overall results – Abstract #156
High prevalence of SMM – Abstract #151 No increased COVID with MGUS – Abstract #154 New FreeLite reference levels – Abstract #542
4
iStopMM abstracts for ASH 2 poster presentations Circulating plasma cells – Abstract #2645 Selection bias in prior MGUS studies –
Abstract #1618
5
iStopMM: Overall Results Abstract #156 Over 75,000 individuals screened “MGUS positive” patients randomized (3,725): No further contact (1,164) Periodic follow-up (1,159) Intensive diagnostic testing/ monitoring (1,164) 6 Abstract #156 - https://ash.confex.com/ash/2021/webprogram/Paper152333.html
iStopMM: Overall Results Abstract #156 Many more disease diagnoses in group 3 including: SMM + active MM ( + amyloid) Waldenstrom’s
CLL Lymphoma (NHL) 7 Abstract #156 - https://ash.confex.com/ash/2021/webprogram/Paper152333.html
iStopMM: Overall Results Abstract #156
8 Abstract #156 - https://ash.confex.com/ash/2021/webprogram/Paper152333.html
Unexpectedly high prevalence of SMM Abstract #151 0.5% in persons over age 40 years
Abstract #151 - https://ash.confex.com/ash/2021/webprogram/Paper148617.html
9
No increased occurrence of COVID-19 in MGUS Patients - Abstract #154
10 Abstract #154 - https://ash.confex.com/ash/2021/webprogram/Paper153145.html
Circulating plasma cells in MGUS/ SMM/ MM - Abstract #2645 Discussion of iStopMM data
11 Abstract #2645 - https://ash.confex.com/ash/2021/webprogram/Paper146363.html
Many diverse outcomes of iStopMM Tumor microenvironment Risk scores MGRS
Pain Flow cytometry
Cancer screening
Renal amyloidosis Genetics Mental health Early intervention
Correlative science
Neuropathy Survival
Cardiac amyloidosis
Psychological impact
The significance of the “unknown significance”
Polyclonal immunoglobulins Waldenströms
iStopMM Outcomes Value of screening (from randomized trial) will be clear during 2022 Additional results are highly anticipated including full sequence data and immune monitoring
13
Identifying NGF algorithm for MGUS Abstract #541: Spanish Team collaboration 5,114 patients with plasma cell disorders studied 3 parameters identified In training datasets rates of progression @ 5 years: “MGUS phenotype” – Zero “Intermediate/ SMM” – 54% “Multiple myeloma” – 66% Abstract #541 - https://ash.confex.com/ash/2021/webprogram/Paper150092.html
14
High prevalence of MGUS in Black/ AA Cohort Abstract #152: First results of PROMISE Study 2,960 individuals over 40 years screened High risk with family history included Prevalance of 10% in PROMISE cohort (BioBank = 9.4%) 15 Abstract #152 - https://ash.confex.com/ash/2021/webprogram/Paper149868.html
CESAR Trial Update: Abstract #1829 Maria-Victoria Mateos, MD, PHD
PFS 94% @ 55 months Sustained MRD negative 67% @ 12 months
Abstract #1829 - https://ash.confex.com/ash/2021/webprogram/Paper148423.html
NOTE: Abstract # 2749: IRd in HR SMM -- CR = 21.8% https://ash.confex.com/ash/2021/webprogram/Paper149787.html
16
Machine learning tool to predict undetectable MRD - Abstract #1596 Studied in ASCT-eligible MM Excellent correlations with outcomes. Effective “weighted” factors: t(4;14) and/or 17 p Level of PCs in bone marrow + PB Immune markers: CD27- ; CD 38+ ; CD56+ Abstract #1596 - https://ash.confex.com/ash/2021/webprogram/Paper145968.html
17
Response assessed by IFE, NGF and Mass Spec - Abstract #544
18 Abstract #544 - https://ash.confex.com/ash/2021/webprogram/Paper151557.html
Dara + VRd Frontline: GRIFFIN Abstract #79
Updated results: Dara + VRd vs. VRd Now 24 months maintenance – R ± Dara
19 Abstract #79 - https://ash.confex.com/ash/2021/webprogram/Paper149024.html
Dara + VRd Frontline: GRIFFIN Abstract #79
Updated responses and MRD
20 Abstract #79 - https://ash.confex.com/ash/2021/webprogram/Paper149024.html
MRD Testing in CASSIOPEIA study Abstract #82 – Part 1 and 2 MRD
NOTE: Q8W Dara maintenance did not improve MRD negativity Abstract #82 - https://ash.confex.com/ash/2021/webprogram/Paper147897.html
21
Clinical Outcomes after Bispecifics Therapy - Abstract #821 (Mount Sinai, NY) Data for 64 RRMM patients ORR of 58% after bi-specific therapy 18 patients transitioned to CAR T: PFS 28.9 months (OS not reached) Encouraging results Further studies needed to assess best sequencing Abstract #821 - https://ash.confex.com/ash/2021/webprogram/Paper151585.html
22
Therapy after CAR T treatment (ide-cel) Abstract #2743 KarMMa Trial follow-up 68 patients with subsequent therapy including anti-BCMA PFS 2 longer than 13 months OS = 24.8 – 31 months Longer follow-up required to assess all outcomes 23 Abstract #2743 - https://ash.confex.com/ash/2021/webprogram/Paper147990.html
Results with talquetamab (anti-GPRC5D + Dara)
Abstract #161: Multi-center trial
Small study so far: 23 patients 3 dose cohorts Tolerable safety profile Promising efficacy Abstract #158: single agent data in 95 patients continues promising results https://ash.confex.com/ash/2021/webprogram/Paper146868.html Abstract #161 - https://ash.confex.com/ash/2021/webprogram/Paper148813.html
24
Results with REGN 5458 (BCMA/ CD3) Abstract #160: Multi-center trial 68 patients ORR = 73.3% (at 96 + 200 mg doses) CRs noted in 48.1% of responders Acceptable safety/ tolerability Overall promising results! 25 Abstract #160 - https://ash.confex.com/ash/2021/webprogram/Paper144921.html
Iberdomide (CelMod) in RRMM Abstract #162 Results for 107 patients with relapsed/refractory MM (RRMM)
26 Abstract #162 - https://ash.confex.com/ash/2021/webprogram/Paper147704.html
COVID-19 Status Reports 10 abstracts (including iStopMM) Follow-up Spanish data 1 over (Abstract #2719) 451 patients Key factors remain: Male/ Over age 65 years/ Active MM Poor antibody responses to vaccines; boosters required Specific concerns about anti-BCMA and anti-CD38 (impact of omicron variant unknown) Abstract #2719 - https://ash.confex.com/ash/2021/webprogram/Paper149192.html
27
Summary Takeaways for ASH 2021 Overview Additional important observations ??
28
Thank you to our sponsors!
29